Press Releases   Media Coverage     PRESS RELEASES   MANIPAL ACUNOVA CONFERRED "PROXIMARE'S INDIA'S BEST EMERGING CRO OF 2005" AWARD   Bangalore, October 07th, 2005 - Manipal AcuNova, a leading player in biotechnology and clinical research, is 'India's best emerging CRO' according to a survey conducted by Proximare. The award was conferred in a function held on October 5 in Mumbai, India.   Speaking about the award, Mr. D A Prasanna, Vice Chairman and Managing Director, Manipal AcuNova, said, "Access to patients and experienced investigators is key to research. Manipal AcuNova is fortunate to have access to the Manipal Teaching Hospitals. We have 90 highly qualified professionals working at our state- of-art research centres. In a short period, clients have been happy with our research. This award encourages us to aim high in the future".   Mr. Nailesh A. Bhatt, Managing Director of Proximare said, "We are pleased to announce the winners in this category. These companies are pioneers and have created significant and impressive infrastructure to provide valuable services to the global clinical research industry...Key benefits of this report are that they are comprehensive, neutral and allows the reader to understand the overall clinical research industry landscape in India as well as specifics about every CRO," he added.   Proximare Inc is a New Jersey based leading strategic management consulting firms that develops and implements growth strategies for pharmaceutical and biotech. It carried out a comprehensive and neutral analysis of India's clinical research industry, including thirty three CROs. Benchmarking of every CRO was done on five key elements: Management, Project Experience, Manpower, Infrastructure and Financial Strength.   Medical Directors from Allergan, Aventis Pharma and Targacept Inc have had a positive experience in the trials they have conducted through Manipal AcuNova. Dr. Shah, VP - Medical & Regulatory affairs said that AstraZeneca is satisfied at the research recently conducted by Manipal AcuNova.   Go back to press release

Privacy Policy     Disclaimer